Song, Y.; Pan, S.; Tian, J.; Yu, Y.; Wang, S.; Qiu, Q.; Shen, Y.; Yang, L.; Liu, X.; Luan, J.;
et al. Activation of CD14+ Monocytes via the IFN-γ Signaling Pathway Is Associated with Immune-Related Adverse Events in Hepatocellular Carcinoma Patients Receiving PD-1 Inhibition Combination Therapy. Biomedicines 2024, 12, 1140.
https://doi.org/10.3390/biomedicines12061140
AMA Style
Song Y, Pan S, Tian J, Yu Y, Wang S, Qiu Q, Shen Y, Yang L, Liu X, Luan J,
et al. Activation of CD14+ Monocytes via the IFN-γ Signaling Pathway Is Associated with Immune-Related Adverse Events in Hepatocellular Carcinoma Patients Receiving PD-1 Inhibition Combination Therapy. Biomedicines. 2024; 12(6):1140.
https://doi.org/10.3390/biomedicines12061140
Chicago/Turabian Style
Song, Yaoru, Shida Pan, Jiahe Tian, Yingying Yu, Siyu Wang, Qin Qiu, Yingjuan Shen, Luo Yang, Xiaomeng Liu, Junqing Luan,
and et al. 2024. "Activation of CD14+ Monocytes via the IFN-γ Signaling Pathway Is Associated with Immune-Related Adverse Events in Hepatocellular Carcinoma Patients Receiving PD-1 Inhibition Combination Therapy" Biomedicines 12, no. 6: 1140.
https://doi.org/10.3390/biomedicines12061140
APA Style
Song, Y., Pan, S., Tian, J., Yu, Y., Wang, S., Qiu, Q., Shen, Y., Yang, L., Liu, X., Luan, J., Wang, Y., Wang, J., Fan, X., Meng, F., & Wang, F.-S.
(2024). Activation of CD14+ Monocytes via the IFN-γ Signaling Pathway Is Associated with Immune-Related Adverse Events in Hepatocellular Carcinoma Patients Receiving PD-1 Inhibition Combination Therapy. Biomedicines, 12(6), 1140.
https://doi.org/10.3390/biomedicines12061140
